Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Stroke | Research article

Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study

Authors: Qi Zhao, Li Wang, Paul A. Kurlansky, Jeff Schein, Onur Baser, Jeffrey S. Berger

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Coronary artery disease accelerates heart failure progression, leading to poor prognosis and a substantial increase in morbidity and mortality. This study was aimed to assess the impact of coronary artery disease on all-cause mortality, myocardial infarction (MI), and ischemic stroke (IS) among hospitalized newly-diagnosed heart failure (HF) patients with left ventricular systolic dysfunction (LVSD).

Methods

This retrospective cohort study included Medicare patients (aged ≥65 years) with ≥1 inpatient heart failure claim (index date = discharge date) during 01JAN2007-31DEC2013. Patients were required to have continuous enrollment for ≥1-year pre-index date (baseline: 1-year pre-index period) without a prior heart failure claim (in the 1 year pre-index prior to the index hospital admission); follow-up ran from the index date to death, disenrollment from the health plan, or the end of the study period, whichever occurred first. HF with LVSD patients, identified with diagnosis codes of systolic dysfunction (excluding baseline atrial fibrillation), were stratified based on prevalent coronary artery disease at baseline into coronary artery disease and non-coronary artery disease cohorts. Main outcomes were occurrence of major adverse cardiovascular events including all-cause mortality, myocardial infarction, and ischemic stroke. Propensity score matching (PSM) was used to balance patient characteristics. Kaplan-Meier curves of ACM and cumulative incidence distribution of MI/IS were presented.

Results

Of 22,230 HF with LVSD patients, 15,827 (71.2%) had coronary artery disease and were overall more likely to be younger (79.8 vs 80.9 years), male (49.6% vs. 35.6%), white (86.2% vs 81.4%), with more prevalent comorbidities including hypertension (80.7% vs 74.3%), hyperlipidemia (67.7% vs 46.7%), and diabetes (46.3% vs 35.8%) (all p < 0.0001). After propensity score matching, cohorts included 5792 patients each. The coronary artery disease cohort had significantly higher cumulative incidence of myocardial infarction and ischemic stroke at the end of 7-year follow-up vs non-coronary artery disease (myocardial infarction = 50.0% vs 18.0%; ischemic stroke = 23.3% vs 18.7%; all p < 0.0001). Follow-up all-cause mortality rates were similar between the two cohorts.

Conclusions

HF with LVSD patients with coronary artery disease had significantly higher incidence of ischemic stroke and myocardial infarction, but similar all-cause mortality compared to those without coronary artery disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lala A, Desai AS. The role of coronary artery disease in heart failure. Heart Fail Clin. 2014;10(2):353–65.CrossRef Lala A, Desai AS. The role of coronary artery disease in heart failure. Heart Fail Clin. 2014;10(2):353–65.CrossRef
2.
go back to reference Obi EN, Swindle JP, Turner SJ, Russo PA, Altan A. Healthcare costs among patients with heart failure: a comparison of costs between matched decedent and survivor cohorts. Adv Ther. 2017;34(1):261–76.CrossRef Obi EN, Swindle JP, Turner SJ, Russo PA, Altan A. Healthcare costs among patients with heart failure: a comparison of costs between matched decedent and survivor cohorts. Adv Ther. 2017;34(1):261–76.CrossRef
4.
go back to reference Mujib M, Rahman AA, Desai RV, Ahmed MI, Feller MA, Aban I, et al. Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. Am J Cardiol. 2011;107(4):552–7.CrossRef Mujib M, Rahman AA, Desai RV, Ahmed MI, Feller MA, Aban I, et al. Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. Am J Cardiol. 2011;107(4):552–7.CrossRef
5.
go back to reference Taylor CJ, Hobbs FR. Heart failure therapy in patients with coronary artery disease. Curr Opin Pharmacol. 2013;13(2):205–9.CrossRef Taylor CJ, Hobbs FR. Heart failure therapy in patients with coronary artery disease. Curr Opin Pharmacol. 2013;13(2):205–9.CrossRef
6.
go back to reference Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin. 2007;25(4):487–95.CrossRef Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin. 2007;25(4):487–95.CrossRef
7.
go back to reference Ghali JK, Massie BM, Mann DL, Rich MW. Guidelines, performance measures, and the practice of medicine: mind the gap. J Card Fail. 2010;16(12):915–8.CrossRef Ghali JK, Massie BM, Mann DL, Rich MW. Guidelines, performance measures, and the practice of medicine: mind the gap. J Card Fail. 2010;16(12):915–8.CrossRef
8.
go back to reference Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014;1(2):110–45.CrossRef Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014;1(2):110–45.CrossRef
9.
go back to reference Lavoie L, Khoury H, Welner S, Briere JB. Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review. Cardiovasc Ther. 2016;34(3):152–60.CrossRef Lavoie L, Khoury H, Welner S, Briere JB. Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review. Cardiovasc Ther. 2016;34(3):152–60.CrossRef
10.
go back to reference Ferreira JP, Girerd N, Alshalash S, Konstam MA, Zannad F. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. Eur Heart J. 2016;37(31):2455–64.CrossRef Ferreira JP, Girerd N, Alshalash S, Konstam MA, Zannad F. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. Eur Heart J. 2016;37(31):2455–64.CrossRef
11.
go back to reference Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemostasis. 2015;114(06):1277–89. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemostasis. 2015;114(06):1277–89.
12.
go back to reference Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2):559–65.CrossRef Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2):559–65.CrossRef
13.
go back to reference Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26(24):4027.CrossRef Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26(24):4027.CrossRef
14.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal). 2016;74(10):1037–147.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal). 2016;74(10):1037–147.CrossRef
15.
go back to reference Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016;10(1):3.CrossRef Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016;10(1):3.CrossRef
16.
go back to reference Murad K, Kitzman DW. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev. 2012;17(4–5):581–8.CrossRef Murad K, Kitzman DW. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev. 2012;17(4–5):581–8.CrossRef
17.
go back to reference Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail. 2014;16(9):967–76.CrossRef Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail. 2014;16(9):967–76.CrossRef
18.
go back to reference Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754–63.CrossRef Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754–63.CrossRef
19.
go back to reference Hernandez AF, Hammill BG, Kociol RD, Eapen ZJ, Fonarow GC, Klaskala W, et al. Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. J Card Fail. 2013;19(6):401–7.CrossRef Hernandez AF, Hammill BG, Kociol RD, Eapen ZJ, Fonarow GC, Klaskala W, et al. Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. J Card Fail. 2013;19(6):401–7.CrossRef
20.
go back to reference Ferrat E, Paillaud E, Laurent M, Le Thuaut A, Caillet P, Tournigand C, et al. Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. J Gerontol A Biol Sci Med Sci. 2015;70(9):1148–55.CrossRef Ferrat E, Paillaud E, Laurent M, Le Thuaut A, Caillet P, Tournigand C, et al. Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. J Gerontol A Biol Sci Med Sci. 2015;70(9):1148–55.CrossRef
21.
go back to reference Zannad F, Greenberg B, Cleland JG, Gheorghiade M, Van Veldhuisen DJ, Mehra MR, et al. Rationale and design of a randomized, double-blind, event driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail. 2015;17(7):735–42.CrossRef Zannad F, Greenberg B, Cleland JG, Gheorghiade M, Van Veldhuisen DJ, Mehra MR, et al. Rationale and design of a randomized, double-blind, event driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail. 2015;17(7):735–42.CrossRef
22.
go back to reference Zannad F, Anker SD, Byra WM, Cleland JG, Fu M, Gheorghiade M, et al. Rivaroxaban in patients with heart failure, sinus rhythm. and coronary disease. New Engl J Med. 2018;379(14):1332–42.CrossRef Zannad F, Anker SD, Byra WM, Cleland JG, Fu M, Gheorghiade M, et al. Rivaroxaban in patients with heart failure, sinus rhythm. and coronary disease. New Engl J Med. 2018;379(14):1332–42.CrossRef
23.
go back to reference Pullicino PM, McClure LA, Howard VJ, Wadley VG, Safford MM, Meschia JF, et al. Identifying a high stroke risk subgroup in individuals with heart failure. J Stroke. Cerebrovascular Dis. 2013;22(5):620–6.CrossRef Pullicino PM, McClure LA, Howard VJ, Wadley VG, Safford MM, Meschia JF, et al. Identifying a high stroke risk subgroup in individuals with heart failure. J Stroke. Cerebrovascular Dis. 2013;22(5):620–6.CrossRef
24.
go back to reference Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314(10):1030–8.CrossRef Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314(10):1030–8.CrossRef
25.
go back to reference Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2014;3:CD003336. Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2014;3:CD003336.
Metadata
Title
Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study
Authors
Qi Zhao
Li Wang
Paul A. Kurlansky
Jeff Schein
Onur Baser
Jeffrey S. Berger
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0991-1

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue